United States - English - NLM (National Library of Medicine)

cvs pharmacy - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - skin protectant • helps treat and prevent diaper rash • protects chafed skin due to the diaper rash and helps seal out wetness - condition worsens - symptoms last more than 7 days or clear up and occur again within a few days

United States - English - NLM (National Library of Medicine)

innovus pharmaceuticals, inc. - zinc acetate (unii: fm5526k07a) (zinc cation - unii:13s1s8sf37), zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37) - reduces duration of a common cold - reduces duration of a common cold - reduces duration of cold symptoms: sneezing sore throat stuffy nose coughing congestion - sneezing - sore throat - stuffy nose - coughing - congestion aytumune oral spray is formulated to reduce the duration of a common cold and may not  be effective for flu or allergies.  a sensitivity to zinc or are allergic to zinc symptoms persist or if accompanied by fever.

United States - English - NLM (National Library of Medicine)

innovus pharmaceuticals, inc. - zinc acetate (unii: fm5526k07a) (zinc cation - unii:13s1s8sf37), zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37) - reduces duration and severity of the common cold - reduces duration of the common cold - helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion - sore throat - stuffy nose - sneezing - coughing - nasal congestion aytumune is formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. a sensitivity to zinc or are allergic to zinc symptoms persist or are accompanied by a fever or new symptoms occur

Philippines - English - FDA (Food And Drug Administration)

amb hk enterprises, inc.; distributor: bell-kenz pharma inc. - ascorbic acid , zinc - capsule - 500 mg/10 mg (equivalent to 27.50 mg zinc sulfate monohydrate)

Philippines - English - FDA (Food And Drug Administration)

eurocare pharma inc.; distributor: unilab, inc. - ascorbic acid , zinc - capsule - 500 mg (equivalent to 562.42 mg sodium ascorbate)/10 mg (equivalent to 27.5 mg zinc sulfate monohydrate)

Philippines - English - FDA (Food And Drug Administration)

eurocare pharma, inc.; distributor: unilab, inc. - ascorbic acid , zinc - capsule - 500mg (equivalent to 562.42mg sodium ascorbate) / 10mg (equivalent to 27.5mg zinc sulfate monohydrate)

Philippines - English - FDA (Food And Drug Administration)

medhaus pharma, incorporated - zinc (as gluconate) - syrup - 10mg elemental zinc (equi. to 70mg zinc gluconate) per 5ml

United States - English - NLM (National Library of Medicine)

piramal critical care inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [ see warnings and precautions ( 5.6) ]. risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc. parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration ( 2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions ( 5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients. in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [see warnings and precautions (5.6)] . risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc. parenteral nutrition with zinc should be considered if a pregnant woman's nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration (2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients. in general, dose selection should be individualized based on the patient's clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

Philippines - English - FDA (Food And Drug Administration)

shalaks pharmaceuticals, inc.; distributor: shalaks pharmaceuticals, inc. - multivitamins , minerals (vet.) - tablet - formulation: each tablet contains: calcium...... 210 mg vitamin a.. ..3500 iu potassium..80 mg vitamin d..1000 iu magnesium...75 mg vitamin e...60 iu chloride...72 mg vitamin c...120 mg niacin (vitamin b1)...20 mg pantothenic acid (vitamin b5)......10 mg phosphorus..20 mg zinc.......15 mg vitamin b6.. 6 mg manganese....4 mg iodine....150 mcg riboflavin (vitamn b2)....1.7 mg thiamin (vitamin b1)...1.5 mg folic acid (vitamin b9).. 300 mcg chromium...60 mcg molybdenum....50 mcg vitamin b12..100 mcg vitamin k.. ..60 mcg selenium...21 mcg vanadium..10 mcg nickel....5 mcg biotin (vitamin b7).. ...30 mcg silicon..2 mg copper..0.5 mg lutein..300 mcg lycopene....600 mcg